Skip to main content
Clinical Trials/NCT05270239
NCT05270239
Completed
Not Applicable

Neurorehabilitation and Functional Recovery in Multiple Sclerosis: Assessing Two Therapeutic Strategies Using Functional Magnetic Resonance Imaging.

Universitat Jaume I1 site in 1 country94 target enrollmentMay 27, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
Universitat Jaume I
Enrollment
94
Locations
1
Primary Endpoint
Change from baseline in Omissions
Status
Completed
Last Updated
last year

Overview

Brief Summary

Multiple sclerosis (MS) is an autoimmune disease that causes cognitive and motor disabilities and contributes to decrease patients life quality. Previous results described that there are some MS patients that showed (at least in some phases of the disease) neuroplasticity processes that are able to compensate some cognitive deficits. Moreover, neuroplasticity processes seem to be limited and related to the degree of gray matter atrophy (patients with less atrophy show grater neuroplasticity than those with higher atrophy level). The aims of this project are:

  1. to study behavioral changes (post-training) induced by two different rehabilitation programs: a)cognitive training focused on exclusively enhancing working memory and b) aerobic + cognitive training aimed to enhance attention, working memory processes and motor capabilities using a virtual reality game.
  2. to study neuroplasticity changes (post-training functional connectivity changes) induced by these rehabilitation programs
  3. to observe the role of the atrophy in brain neuroplasticity processes.

Neuropathological status and neuroplasticity processes (studied using neuroimaging tools) as well as cognitive performance using neuropsychological tools will be assessed in a group of MS patients (with different phenotypes) at two different time points: before any training (S1) and after 10 days of training (S2). This project will be financed by the Ministerio de ciencia, innovación y universidades of the Spanish government and also have been approved by the Ethical committee of Universitat Jaume I.

Registry
clinicaltrials.gov
Start Date
May 27, 2022
End Date
July 31, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Universitat Jaume I
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Multiple Sclerosis Diagnosis.

Exclusion Criteria

  • Other neurological pathologies comorbidity.
  • Magnetic resonance imaging incompatibilities.
  • Motor impairment degree that impede the task performance.

Outcomes

Primary Outcomes

Change from baseline in Omissions

Time Frame: Baseline and 10 training days after.

In both tasks will be assessed the number of times that a correct stimulus appear and non-response is given.

Change from baseline in Functional Connectivity in resting state

Time Frame: Baseline and 10 training days after.

This is a brain activity measure during resting state through functional magnetic resonance imaging. This outcome will be assessed in both studies. fMRI sequence: T2-weighted echoplanar imaging sequence.

Change from baseline in Letters and Numbers

Time Frame: Baseline and 10 training days after.

A WAIS-III subtest that measures working memory.

Change from baseline in SRT-S: Selective Reminding Test (Storing)

Time Frame: Baseline and 10 training days after.

A subtest of the BRB-N (The Brief Repeatable Battery of Neuropsychological Tests for MS) which measures memory storage capacity.

Change from baseline in SRT-R: Selective Reminding Test (Retrieval)

Time Frame: Baseline and 10 training days after.

This subtest of the BRB-N is a measure of memory retrieval capacity.

Change from baseline in SDMT: Symbol Digit Modalities Test

Time Frame: Baseline and 10 training days after.

A BRB-N subtest which measures information processing speed.

Change from baseline in PASAT: Paced Auditory Serial Addition Task

Time Frame: Baseline and 10 training days after.

A BRB-N subtest which measures working memory.

Change from baseline in Digit Span Backward

Time Frame: Baseline and 10 training days after.

A WAIS-III subtest that is a working memory measure.

Change from baseline in Correct Responses

Time Frame: Baseline and 10 training days after.

Number of correct responses in both tasks (n-back computerized task and balls Virtual Reality task)

Change from baseline in Reaction Time

Time Frame: Baseline and 10 training days after.

This is a primary outcome of the n-back task, which refers to the amount of time (in milliseconds) that elapse from the moment the correct stimulus appears and the correct response is given.

Change from baseline in Errors

Time Frame: Baseline and 10 training days after.

The number of times that a distractor stimulus appears and a response is given.

Change from baseline in Functional Connectivity in task performance

Time Frame: Baseline and 10 training days after.

This is a brain activity measure during a task performance through functional magnetic resonance imaging. This outcome will be assessed in Virtual Reality study. fMRI sequence: T2-weighted echoplanar imaging sequence.

Change from baseline in SPART-D: Spatial Recall Test (Delayed)

Time Frame: Baseline and 10 training days after.

This BRB-N subtest measures the spatial delayed memory.

Change from baseline in Semantic Fluency

Time Frame: Baseline and 10 training days after.

A language measure that assesses semantic fluency.

Change from baseline in SRT-D: Selective Reminding Test (Delayed)

Time Frame: Baseline and 10 training days after.

This BRB-N subtest measures the delayed memory.

Change from baseline in SPART: Spatial Recall Test

Time Frame: Baseline and 10 training days after.

A subtest of the BRB-N that measures spatial memory.

Change from baseline in Phonemic Fluency

Time Frame: Baseline and 10 training days after.

A language measure that assesses phonemic fluency.

Change from baseline in Digit Span Forward

Time Frame: Baseline and 10 training days after.

A subtest of the Wechsler Adult Intelligence Scale (WAIS-III) that is an attention measure.

Secondary Outcomes

  • Brain Parenchymal Fraction (BPF)(Baseline)
  • Cortical Lesions(Baseline)
  • Lesion Volume in white matter tissue(Baseline)
  • Total Intracranial Volume (TIV)(Baseline)
  • Cortical Thickness(Baseline)

Study Sites (1)

Loading locations...

Similar Trials